Fiche publication
Date publication
janvier 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier
,
Pr BORG Christophe
,
Pr PIVOT Xavier
,
Dr ROYER Bernard
Tous les auteurs :
Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O
Lien Pubmed
Résumé
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. Besides, mammalian target of rapamycin inhibition has the ability to modulate T-lymphocyte homeostasis. Here, we report the case of a metastatic renal cell carcinoma patient treated with everolimus who presented unexpected prolonged tumor response. The monitoring of immune responses showed strong antitumor T-cell activation at the time of disease control, whereas a profound immunosuppression occurred when tumor progressed. Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy.
Référence
J Immunother. 2014 Jan;37(1):51-4
